华盛顿,1月29日(UPI)——根据一项新的研究，血压药物坎地沙坦（candesartan）是可以减少细胞损伤延缓阿尔茨海默病的发展。
血管紧张素受体阻滞剂之一如Atacand可用来控制血压。研究显示高血压用药物治疗患者阿尔茨海默氏症的风险降低或发展更加缓慢。
乔治敦大学的研究员在一份新闻稿说:"我们的发现在许多方面都很有意义"。"高血压使整个的身体和大脑血流量降低，是老年痴呆症的危险因素。以往的流行病学研究发现ARB类药物治疗的高血压患者同时也延迟阿兹海默症的恶化。
研究人员发现该药可防止炎症和延缓神经元淀粉样变（淀粉样斑块积聚是阿尔茨海默病的主要病理变化）。
The drug candesartan, sold as Atacand, prevented inflammation and other processes that contribute to neuronal death, including changes to amyloid metabolism, which affects the buildup of amyloid plaques typical of Alzheimer's disease patients' brains. Photo by Juan Gaertner/Shutterstock
药物坎地沙坦(Atacand)可防止炎症及其它导致神经元死亡的病变过程，包括淀粉样蛋白代谢的变化（阿尔茨海默病患者的大脑组织典型的淀粉样斑块变）
WASHINGTON, Jan. 29 (UPI) -- The blood pressure drug candesartan, sold as Atacand, was shown to reduce cell damage linked to the progression of Alzheimer's disease, according to a new study.
Angiotensin receptor blockers such as Atacand are one of several drugs used to control blood pressure. Previous studies have shown patients with high blood pressure treated with several drugs were at lower risk to develop Alzheimer's or to develop it more slowly.
"Our findings make sense in many ways," said Dr. Juan Saavedra, a researcher at Georgetown University, in a press release. "Hypertension reduces blood flow throughout the body and brain and is a risk factor of Alzheimer's disease. Previous epidemiological studies found that Alzheimer's progression is delayed in hypertensive patients treated with ARBs."
For the study, published in Alzheimer's Research and Therapy, the researchers exposed neuronal cultures excessive glutamate, an injury factor that causes neurons to die, and treated them with candesartan. The drug prevented glutamate from killing the neurons.
In later analysis, the researchers found the drug prevented inflammation and other processes that contribute to neuronal death, including changes to amyloid metabolism -- important becauase the build-up of amyloid plaques plays a role in the progress of Alzheimer's disease.
Researchers also compared their lab results with autopsy samples from Alzheimer's patients, finding the expression of genes altered by excess glutamate matched damage in the patients' brains.
"We hypothesize that candesartan, or other members of the ARB group, may not only slow progression of Alzheimer's but also prevent or delay its development," Saavedra said of the drug with is already approved for use by the U.S. Food and Drug Administration, making the path to clinical trials for the use easier and faster.
Like Us on Facebook for more stories from UPI.com
Related UPI Stories
Memory drug enters clinical trial, may help treat cognitive disorders
Stress in older adults may trigger mild cognitive impairment
Alcohol may reduce risk of death during early-stage Alzheimer's disease
苏公网安备